ConductScience.org, home

Paper28129253

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

Kityo C and 14 others. J Acquir Immune Defic Syndr, 2017. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. Papers, record 28129253. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28129253

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
PubMed
Journal
J Acquir Immune Defic Syndr
PubMed
Year
2017
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
1.32
iCite
Revised in PubMed
2026-01-27
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kityo CCissy
2Thompson JJennifer
3Nankya IImmaculate
4Hoppe AAnne
5Ndashimye EEmmanuel
6Warambwa CColin
7Mambule IIvan
8van Oosterhout JJJoep J
9Wools-Kaloustian KKara
10Bertagnolio SSilvia
11Easterbrook PJPhilippa J
12Mugyenyi PPeter
13Walker ASA Sarah
14Paton NINicholas I
15Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial TeamGroup

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
Drug Resistance, ViralMajor topic
HIV InfectionsMajor topic
HIV-1Major topic
Reverse Transcriptase InhibitorsMajor topic
Adult
Africa South of the Sahara
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Female
HIV Reverse Transcriptase
Humans
Male
Middle Aged
Mutation
Treatment Failure
Viral Load

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Wellcome TrustUnited KingdomPubMedPubMed
001World Health OrganizationInternationalPubMedPubMed
MC_UU_12023/23Medical Research CouncilUnited KingdomPubMedPubMed
U01 AI069911NIAID NIH HHSUnited StatesU01AI069911PubMed and NIHNIH RePORTER

Download CSV of grants

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116890837The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.Lancet2006https://conductscience.org/library/papers/16890837PubMed
224998532Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.J Int AIDS Soc2014https://conductscience.org/library/papers/24998532PubMed
316076886An automated genotyping system for analysis of HIV-1 and other microbial sequences.Bioinformatics2005https://conductscience.org/library/papers/16076886PubMed
426807968Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.AIDS2016https://conductscience.org/library/papers/26807968PubMed
523687292Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.J Infect Dis2013https://conductscience.org/library/papers/23687292PubMed
619604043
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
J Infect Dis2009https://conductscience.org/library/papers/19604043PubMed
719578237HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.Antivir Ther2009https://conductscience.org/library/papers/19578237PubMed
821848790The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.HIV Med2012https://conductscience.org/library/papers/21848790PubMed
9251015292014 Update of the drug resistance mutations in HIV-1.Top Antivir Med2014https://conductscience.org/library/papers/25101529PubMed
1024795328Drug susceptibility and resistance mutations after first-line failure in resource limited settings.Clin Infect Dis2014https://conductscience.org/library/papers/24795328PubMed
1120964479Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.AIDS Res Hum Retroviruses2011https://conductscience.org/library/papers/20964479PubMed
1223727942Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.AIDS2013https://conductscience.org/library/papers/23727942PubMed
1323991055High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.PLoS One2013https://conductscience.org/library/papers/23991055PubMed
1419417582The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.AIDS2009https://conductscience.org/library/papers/19417582PubMed
1522842995Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.AIDS2013https://conductscience.org/library/papers/22842995PubMed
1622474222Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.Clin Infect Dis2012https://conductscience.org/library/papers/22474222PubMed
1722403431Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.J Clin Microbiol2012https://conductscience.org/library/papers/22403431PubMed
1820163340Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.Curr HIV Res2010https://conductscience.org/library/papers/20163340PubMed
1927732929No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.J Infect Dis2016https://conductscience.org/library/papers/27732929PubMed
2020188624Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.J Clin Virol2010https://conductscience.org/library/papers/20188624PubMed

See all 29 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
41482685Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.Clin Infect Dis2026https://conductscience.org/library/papers/41482685PubMed
39339151Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication.Pharmaceutics2024https://conductscience.org/library/papers/39339151PubMed
38020274Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era.J Public Health Afr2023https://conductscience.org/library/papers/38020274PubMed
35854413A Case Report of Multiclass HIV Drug-Resistance After an Inappropriate Switch of ARVs with Persistent Unsuppressed Viral Load.J Int Assoc Provid AIDS Care2022https://conductscience.org/library/papers/35854413PubMed
35458459Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.Viruses2022https://conductscience.org/library/papers/35458459PubMed
34741609Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.J Antimicrob Chemother2022https://conductscience.org/library/papers/34741609PubMed
32119691HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.PLoS One2020https://conductscience.org/library/papers/32119691PubMed
32005262Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.AIDS Res Ther2020https://conductscience.org/library/papers/32005262PubMed
31969438Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.J Virol2020https://conductscience.org/library/papers/31969438PubMed
30977467Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.Antivir Ther2019https://conductscience.org/library/papers/30977467PubMed
30304061HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.PLoS One2018https://conductscience.org/library/papers/30304061PubMed
30053052Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.J Antimicrob Chemother2018https://conductscience.org/library/papers/30053052PubMed
30032305Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.J Antimicrob Chemother2018https://conductscience.org/library/papers/30032305PubMed
29661246Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.AIDS Res Ther2018https://conductscience.org/library/papers/29661246PubMed
29293156HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.J Acquir Immune Defic Syndr2018https://conductscience.org/library/papers/29293156PubMed
29283390Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.Viruses2017https://conductscience.org/library/papers/29283390PubMed
29206999Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.J Infect Dis2017https://conductscience.org/library/papers/29206999PubMed
29108797
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Lancet Infect Dis2018https://conductscience.org/library/papers/29108797PubMed
28968669Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.J Infect Dis2017https://conductscience.org/library/papers/28968669PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
MLC123209PubTator's text mininghttps://conductscience.org/library/genes/23209NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28129253

GET https://conductscience.org/api/papers/v1/28129253/references?page=2